



CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Date: 09.08.2024

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal St, Fort, Mumbai,
Maharashtra 400001

Scrip Code: 538965

Dear Sir/Madam,

Sub: Discrepancies in Financial Results Email dated 07.08.2024 received from BSE Limited.

The Queries raised by BSE Limited and our clarifications are as follows:

Query: Standalone Results- Cash Flow Statement for Standalone Results not Received in Pdf for Year Ended - March 2024.

Reply: We hereby enclosing Cash Flow Statement for Standalone Results in PDF format. (Due to a scan error, we erroneously unable to upload the missing document; however, the accurate figures have already been uploaded in XBRL format on the actual date as complied)

This is for the information and records of the Exchange, please.

Thanking you

Yours Sincerely,

For Concord Drugs Limited

SEELAM
NAGI REDDY

Digitally signed by
SEELAM NAGI REDDY
Date: 2024.08.09
10:20:24 +05'30'


NAGI REDDY SEELAM
Chairman & Managing Director
(DIN: 01764665)



Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana
Statement of assets and Liabilities audited (standalone and Consolidated) as on 31st March 2024 Rs In lakhs

Particulars	Note	Standalone		Consolidated	
		As on 31st March, 2024	As At March 31, 2023	As on 31st March , 2024	As At March 31, 2023
ASSETS					
Non-current assets					
(a) Property, plant and equipment	3	1,098.64	1,221.64	1,103.62	1,228.33
(b) Capital Work-in Progress	3	163.05	92.09	163.05	92.09
(b) Investment property	3	63.95	63.95	63.95	63.95
(e) Goodwill	4	-	-	-	-
Financial assets					
(a) Investments	4	161.50	141.50	84.06	89.36
(b) Loans & Advances	4	4.46	3.73	4.46	3.73
Other Non current assets	5	-	-	-	-
Total Non - Current Assets		1,491.61	1,522.90	1,419.14	1,477.45
Current Assets					
Inventories	7	1,849.93	1,750.40	2,292.31	2,006.47
Financial assets					
(a) Investments		-	-	-	-
(b) Trade receivables	6	2,106.95	1,635.42	1,982.67	1,581.01
(c) Cash and cash equivalents	8	13.71	7.52	14.54	7.84
(d) Bank balances other than (c) above	8	3.10	2.10	3.10	2.10
(e) Other Current Financial Assets	9	4.69	14.04	4.69	14.04
Other current assets	10	159.84	730.98	164.20	734.20
Total Current assets		4,138.21	4,140.46	4,461.50	4,345.64
Total Assets		5,629.82	5,663.37	5,880.64	5,823.10
EQUITY AND LIABILITIES					
Equity					
Equity share capital	11	1,000.00	931.55	1,000.00	931.55
Other equity	12	2,381.78	2,238.88	2,381.78	2,238.88
Total Equity		3,381.78	3,170.42	3,381.78	3,170.42
Non-current liabilities					
Financial Liabilities					
(a) Borrowings	13	2.67	101.71	64.54	191.13
(b) Trade payables		-	-	-	-
Deferred tax liabilities, net	14	48.15	54.48	47.33	53.68
Provisions	15	252.88	246.38	252.88	246.38
Government Grants	13	-	-	-	-
Total Non-current liabilities		303.70	402.57	364.76	491.20
Current liabilities					
Financial liabilities					
(a) Borrowings	16	1,398.13	1,378.47	1,594.87	1,422.60
(b) Trade payables	17	354.67	514.52	343.75	527.22
(c) Other Current financial liabilities	18	92.46	82.74	92.46	82.74
Current tax liabilities, net	15	20.24	34.77	22.34	38.12
Other current liabilities	19	78.85	79.86	80.70	90.79
Total Current liabilities		1,944.34	2,090.37	2,134.10	2,161.48
Total liabilities		2,248.04	2,492.94	2,498.86	2,652.67
Total Equity and liabilities		5,629.82	5,663.37	5,880.64	5,823.10

Place: Hyderabad
Date: 30.05.2024

By Order of the Board
For Concord Drugs Limited

S. N. Srinivas
Managing Director
DIN: 01764665



Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana
Statement of standalone assets and Liabilities (audited) as on 31st March 2024 Rs in Lakhs

Particulars	Note	As on 31st March 2024	As on March 31, 2023
ASSETS			
Non-current assets			
(a) Property, plant and equipment	3	1,098.64	1,221.64
(b) Capital Work-in Progress	3	163.05	92.09
(b) Investment property	3	63.95	63.95
Financial assets			
(a) Investments	4	161.50	141.50
(b) Loans & Advances	4	4.46	3.73
Other Non current assets	5		
Total Non - Current Assets		1,491.61	1,522.90
Current Assets			
Inventories	7	1,849.93	1,750.40
Financial assets			
(a) Investments			
(b) Trade receivables	6	2,106.95	1,635.42
(c) Cash and cash equivalents	8	13.71	7.52
(d) Bank balances other than (c) above	8	3.10	2.10
(e) Other Current Financial Assets	9	4.69	14.04
Other current assets	10	159.84	730.98
Total Current assets		4,138.21	4,140.46
Total Assets		5,629.82	5,663.37
EQUITY AND LIABILITIES			
Equity			
Equity share capital	11	1,000.00	931.55
Other equity	12	2,381.78	2,238.88
Total Equity		3,381.78	3,170.42
Non-current liabilities			
Financial Liabilities			
(a) Borrowings	13	2.67	101.71
(b) Trade payables			
Deferred tax liabilities, net	14	48.15	54.48
Provisions	15	252.88	246.38
Government Grants	13		-
Total Non-current liabilities		303.70	402.57
Current liabilities			
Financial liabilities			
(a) Borrowings	16	1,398.13	1,378.47
(b) Trade payables	17	354.67	514.52
(c) Other Current financial liabilities	18	92.46	82.74
Current tax liabilities, net	15	20.24	34.77
Other current liabilities	19	78.85	79.86
Total Current liabilities		1,944.34	2,090.37
Total liabilities		2,248.04	2,492.94
Total Equity and liabilities		5,629.82	5,663.37

Place: Hyderabad
Date: 30.05.2024



By Order of the Board
Concord Drugs Limited

Managing Director
PIN: 01764665

Audited Statement Of Consolidated Profit and Loss for the Period ended 31st March '24 Amount in Lakhs

	Particulars	Note	Standalone		Consolidated	
			As on 31st March 2024	As at March 31, 2023	As on 31st March ,2024	As at March 31, 2023
I	Revenue from Operations					
	a. Net sales from Operations	20	4,326.07	5,131.43	4,492.45	5,208.06
II	Other Income	21	0.93	0.89	0.93	0.89
III	Total Revenue (I+II)		4,327.00	5,132.31	4,493.38	5,208.94
IV	Expenses					
	a. Cost of Material Consumed	22	3,370.81	4,035.53	3,365.90	4,116.16
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-40.49	51.56	-40.49	-15.67
	c. Employees Benefit Expenses	24	495.04	463.42	607.63	491.90
	d. Finance Costs	25	158.98	162.45	186.76	170.62
	e. Depreciation and Amortisation expense	3	153.82	160.25	155.54	162.56
	f. Other expenses	26	132.99	146.56	155.15	158.49
	Total Expenses		4,271.16	5,019.76	4,430.48	5,084.05
	Profit/ (Loss) before Exceptional item and tax (III-IV)		55.84	112.56	62.90	124.89
V	Exceptional Items		-	-	-	-
VI	Profit/ (Loss) before tax (V+VI)		55.84	112.56	62.90	124.89
VII	Tax Expense:		13.90	23.34	15.66	26.34
VIII	a. Current tax		20.24	34.77	22.01	37.87
	b. Deferred tax charge/credit		-6.34	-11.43	-6.36	-11.53
IX	Profit/ (Loss) for the period (VII-VIII)		41.94	89.22	47.24	98.55
X	Other Comprehensive Income		-	-	-	-
	Items that will not be reclassified to profit or loss		-	-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		41.94	89.22	47.24	98.55
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		1,000.00	931.55	1,000.00	931.55
XII	Earnings per share (of Rs. 10 each)					
XIII	a. Basic (in Rs)		0.42	0.96	0.47	1.06
	b. Diluted (in Rs)		0.42	0.96	0.47	1.06

Place: Hyderabad
Date: 30.05.2024



By Order of the Board
For Concord Drugs Limited
S. N. Jay
Managing Director
DIN: 01764665

Audited Statement Of Standalone Profit and Loss for the Period ended 31st March'24

Rs in Lakhs

	Particulars	Note	As on 31st March' 2024	As at March 31, 2023
I	Revenue from Operations			
	a. Net sales from Operations	20	4,326.07	5,131.43
II	Other Income	21	0.93	0.89
III	Total Revenue (I+II)		4,327.00	5,132.31
IV	Expenses			
	a. Cost of Material Consumed	22	3,370.81	4,035.53
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-40.49	51.56
	c. Employees Benefit Expenses	24	495.04	463.42
	d. Finance Costs	25	158.98	162.45
	e. Depreciation and Amortisation expense	3	153.82	160.25
	f. Other expenses	26	132.99	146.56
	Total Expenses		4,271.16	5,019.76
	Profit/ (Loss) before Exceptional item and tax (III-IV)		55.84	112.56
V	Exceptional Items		-	-
VI	Profit/ (Loss) before tax (V+VI)		55.84	112.56
VII	Tax Expense:			
VIII	a. Current tax		13.90	23.34
	b. Deferred tax charge/credit		20.24	34.77
			-6.34	-11.43
IX	Profit/ (Loss) for the period (VII-VIII)		41.94	89.22
X	Other Comprehensive Income			
	Items that will not be reclassified to profit or loss		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		41.94	89.22
XI	Paid-up equity share capital (Face value of the share- Rs. 10 each)		1,000.00	931.55
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.42	0.96
	b. Diluted (in Rs)		0.42	0.96

By Order of the Board
For Concord Drugs Limited

S. N. Jay
Managing Director
DIN: 01764665



Place: Hyderabad
Date: 30.05.2024

STATEMENT OF AUDITED Consolidated FINANCIAL RESULTS FOR THE QUARTER ENDED 31st March 2024

[Rs. in Lakhs]

Particulars	Quarterly ended			Year Ended	
	31-Mar-24 (Audited)	31-Dec-23 (Un Audited)	31-Mar-23 (Audited)	31-Mar-24 (Audited)	31-Mar-23 (Audited)
I Revenue from Operations					
a. Net sales from Operations	1,564.24	1,278.37	1,230.64	4,492.45	5,208.06
b. Other Operating Income	0.11	0.00	0.08	0.93	0.89
II Other Income					
III Total Revenue (I+II)	1,564.36	1,278.37	1,230.71	4,493.38	5,208.94
IV Expenses					
a. Cost of Material Consumed	1,183.24	1,096.16	1,025.05	3,365.90	4,116.16
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	142.04	-84.06	-59.97	-40.49	-15.67
c. Employees Benefit Expenses	169.06	153.93	130.04	607.63	491.90
d. Finance Costs	50.38	49.67	49.83	186.76	170.62
e. Depreciation and Amortisation expense	39.44	38.93	33.03	155.54	162.56
f. Other expenses	34.93	49.43	38.67	155.15	158.49
Total Expenses	1,619.09	1,304.06	1,216.64	4,430.48	5,084.05
Profit/ (Loss) before Exceptional item and tax (III-IV)	-54.73	-25.69	14.07	62.90	124.89
V Exceptional Items	-	-	-	-	-
VI Profit/ (Loss) before tax (V-VI)	-54.73	-25.69	14.07	62.90	124.89
VII Tax Expense:					
a. Current tax	-20.85	-1.57	-2.20	15.66	26.34
b. Deferred tax charge/credit	-19.93	-0.43	5.49	22.01	37.87
IX Profit/ (Loss) for the period (VII-VIII)	-0.92	-1.14	-7.69	-6.36	-11.53
X Other Comprehensive Income	-33.88	-24.12	16.27	47.24	98.55
Items that will not be reclassified to profit or loss	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	-33.88	-24.12	16.27	47.24	98.55
XI Paid up Capital	1,000.00	1,000.00	931.55	1,000.00	931.55
(Face value of the share- Rs. 10 each)					
Other Equity	2,381.78	2,417.05	2,238.88	2,381.78	2,238.88
XII Earnings per share (of Rs. 10 each)					
a. Basic (in Rs)	-0.34	-0.24	0.17	0.47	1.06
b. Diluted (in Rs)	-0.34	-0.24	0.17	0.47	1.06

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above Consolidated financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 30th May, 2024
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- During the year The company has Acquired another 2,00,000 equity Shares of Proton Remedies Private limited(100% subsidiary) by increasing the authorised capital of subsidiary for a total consideration of 20,00,000 (2,00,000 equity shares of Rs.10 each).
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: 30.05.2024By Order of the Board
For Concord Drugs Limited
S. N. Ray
Managing Director
DIN: 01764665

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH 2024

Particulars	Quarterly ended			Year Ended	
	31-Mar-24 (Audited)	31-Dec-23 (un Audited)	31-Mar-23 (Audited)	31-Mar-24 (Audited)	31-Mar-23 (Audited)
I Revenue from Operations					
a. Net sales from Operations	1,446.56	1,262.44	1,154.01	4,326.07	5,131.43
b. Other Operating Income	0.11	0.01	0.08	0.93	0.89
Other Income					
Total Revenue (I+II)	1,446.68	1,262.44	1,154.09	4,327.00	5,132.31
IV Expenses					
a. Cost of Material Consumed	1,279.31	1,043.65	944.42	3,370.81	4,035.53
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-8.96	1.21	7.26	-40.49	51.56
c. Employees Benefit Expenses	125.39	120.33	101.56	495.04	463.42
d. Finance Costs	37.74	43.18	41.66	158.98	162.45
e. Depreciation and Amortisation expense	39.01	38.49	30.72	153.82	160.25
f. Other expenses	32.07	41.11	26.74	132.99	146.56
Total Expenses	1,504.56	1,287.95	1,152.36	4,271.16	5,019.76
Profit/ (Loss) before Exceptional item and tax (III-IV)	-57.88	-25.51	1.73	55.84	112.56
Exceptional Items					
Profit/ (Loss) before tax (V-VI)	-57.88	-25.51	1.73	55.84	112.56
Tax Expense:					
a. Current tax	-22.48	-1.57	-5.20	13.90	23.34
b. Deferred tax charge/credit	-21.58	-0.43	2.39	20.24	34.77
Profit/ (Loss) for the period (VII-VIII)	-90.00	-1.14	-7.59	-6.34	-11.43
Other Comprehensive Income					
Items that will not be reclassified to profit or loss	-35.40	-23.95	6.93	41.94	89.22
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	-35.40	-23.95	6.93	41.94	89.22
XI Paid up Capital					
(Face value of the share- Rs. 10 each)	1,000.00	1,000.00	931.55	1,000.00	931.55
Other Equity					
Earnings per share (of Rs. 10 each)					
a. Basic (in Rs)	2,381.78	2,417.18	2,238.88	2,381.78	2,238.88
b. Diluted (in Rs)	-0.35	-0.24	0.07	0.42	0.96
	-0.35	-0.24	0.07	0.42	0.96

Notes:


- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 30.05.2024
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
- The results are also available on the website of the Company www.concorddrugs.in

Place: Hyderabad
Date: 30.05.2024




By Order of the Board
For Concord Drugs Limited
Managing Director
DIN: 01764665

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana			
Statement Audited Consolidated Cash flow for the year ended 31.03.2024			
Particulars	Amount in Lakhs		
	As on 31st March, 2024	As at March 31, 2023	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax		62.895	124.890
<i>Adjustments for:</i>			
<i>Profit on sale of ASSETS</i>			
Depreciation and amortisation expense	155.539		162.558
Finance costs	186.757		163.712
Interest Income	-0.929		-0.603
Provision for Gratuity			
	341.367		325.667
Operating profit before working capital changes		404.263	450.557
<i>Changes in working capital:</i> (Refer Note 40)			
<i>Adjustments for (increase) / decrease in operating assets:</i>			
Financial Assets			
Trade receivables	-401.665		1,287.924
Loans and Advances	-0.733		-0.543
Other Non Current assets			
Inventories	-285.835		-68.632
Other Current assets	570.000		-593.689
Other bank balances	-1.000		-
Other Current financial Assets	9.350		-3.960
Adjustments for increase / (decrease) in operating liabilities:			
Trade payables			
Borrowings	-183.473		-854.840
Other current financial liabilities			
Other current liabilities	9.713		3.940
Current tax liabilities, net	-10.091		-22.960
Provisions	-15.786		-32.363
Deferred tax on amalgamation	6.500		38.744
Cash generated from operations		101.241	204.178
Net income tax paid		-22.013	-37.874
Net cash flow from operating activities (A)		79.228	166.304
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-101.79		-85.658
Proceeds from maturity of fixed deposits	-		-
Investment			
- Subsidiaries			-141.500
- Others			
	0.929		0.603
Net cash (used in) / flow from investing activities (B)		-100.864	-226.555
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares	68.453		188.668
Finance costs	-186.757		-163.712
Repayment of Borrowings	-126.583		-3.456
Repayment of short term Borrowings	172.261		-15.577
Govt Grants			-
Other equity Adjustment	100.968		56.475
Net cash flow (used in) financing activities (C)		28.342	62.398
Net (decrease) in Cash and cash equivalents (A+B+C)		6.706	2.147
Cash and cash equivalents at the beginning of the year		7.836	5.689
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-	-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		14.54	7.836
* Comprises:			
Balances with Banks		13.71	0.001
Others		0.83	7.836
		14.54	7.836



By Order of the Board
For Concord Drugs Limited
Managing Director
N: 01764665

Place: Hyderabad
Date: 30.05.2024

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511,			
Statement Audited Standalone Cash flow for the year ended 31st March, 2024			
Particulars	Rs in Lakhs		
	As at 31st March, 2024	As at March 31, 2023	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax	55.838	112.557	
<i>Adjustments for:</i>			
<i>Profit on sale of ASSETS</i>			
Depreciation and amortisation expense	153.823	160.25	
Loss / (gain) on sale of PPE (net)	-	-	
Finance costs	158.982	155.54	
Expenses recognised in respect of equity-settled share-based payments	-	-	
Interest income	-0.929	-0.60	
Provision for Gratuity	-	-	
	311.876	315.19	
Operating profit before working capital changes	367.714	427.74	
<i>Changes in working capital:</i> (Refer Note 40)			
<i>Adjustments for (increase) / decrease in operating assets:</i>			
Financial Assets			
Trade receivables	-471.528	650.43	
Loans and Advances	-0.733	-0.54	
Other Non Current assets	-	-	
Inventories	-99.525	-1.41	
Other Current assets	571.137	-593.37	
Other bank balances	-1.000	-	
Other Current financial Assets	9.350	-3.96	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>			
Trade payables	-159.859	-203.36	
Borrowings	-	-	
Other current financial liabilities	9.713	3.94	
Other current liabilities	-1.014	-25.86	
Current tax liabilities, net	-14.531	-32.36	
Provisions	6.500	38.00	
Deferred tax on amalgamation	-	-	
Cash generated from operations	216.223	259.25	
Net income tax paid	-20.237	-34.77	
Net cash flow from operating activities (A)	195.986	224.48	
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-101.79	-85.66	
Proceeds from maturity of fixed deposits	-	-	
Investment	-	-	
- Subsidiaries	-20.000	-141.50	
- Others	0.929	0.60	
Dividend income received	-	-	
- Subsidiary	-	-	
- Others - dividend from mutual funds	-	-	
Net cash (used in) / flow from investing activities (B)	-120.864	-226.56	
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares	58.453	188.67	
Finance costs	-158.982	-155.54	
Repayment of Borrowings	-99.035	-67.74	
Repayment of short term Borrowings	19.658	-16.70	
Govt Grants	-	-	
Other equity Adjustment	100.968	56.48	
Net cash flow (used in) financing activities (C)	-68.938	5.16	
Net (decrease) in Cash and cash equivalents (A+B+C)	6.185	3.08	
Cash and cash equivalents at the beginning of the year	7.525	4.44	
Effect of exchange differences on translation of foreign currency Cash and cash equivalents	-	-	
Cash and cash equivalents at the end of the year (Refer Note (i) below)	13.71	7.52	
* Comprises:			
Balances with Banks	0.00	0.00	
Others	13.71	7.52	
	13.71	7.52	
	By Order of the Board For Concord Drugs Limited		
Place: Hyderabad			
Date: 30.05.2024	Managing Director DIN:01764665		

